Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
47 hedge funds and large institutions have $135M invested in Lumos Pharma, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 4 closing their positions.
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
168% more capital invested
Capital invested by funds: $50.2M → $135M (+$84.3M)
24% more funds holding
Funds holding: 38 → 47 (+9)
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$697K |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$642K |
| 3 |
Bank of New York Mellon
New York
|
+$302K |
| 4 |
6CM
683 Capital Management
New York
|
+$181K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$170K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$93.1K |
| 2 |
IFG
Investors Financial Group
Plymouth,
Minnesota
|
-$61.5K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$41.2K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$38.1K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$33.1K |
LUMO Hedge Fund Activity: Q4 2020 in Review
47 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q4 2020, worth a combined $135M — up 168% from $50.2M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new LUMO positions and 4 closed out — a net gain of 9 holders — while 7 added to existing stakes and 12 trimmed.
The largest buyer was Opaleye Management, adding an estimated $697K. The largest seller was Two Sigma Advisers, cutting an estimated $93.1K.
- 47 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q4 2020, up from 38 in Q3 2020.
- Funds reported $135M of Lumos Pharma, Inc. Common Stock stock for Q4 2020, up 168% quarter-over-quarter.
- 13 funds opened new Lumos Pharma, Inc. Common Stock positions in Q4 2020 and 4 closed out, a net change of +9 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q4 2020 was Opaleye Management, an estimated $697K added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q4 2020 was Two Sigma Advisers, an estimated $93.1K sold.
Based on aggregated 13F filings for Q4 2020.